Excellent Outcome for Pediatric Patients With High-Risk Hodgkin Lymphoma Treated With Brentuximab Vedotin and Risk-Adapted Residual Node Radiation.

Monika L MetzgerMichael P LinkAmy L BillettJamie E Flerlage John T Lucas Belinda N Mandrell Matthew J Ehrhardt Nickhill H BhaktaTorunn I YockAlison M FriedmannPedro de AlarconSandra Luna-FinemanEric LarsenSue C KasteBarry ShulkinZhao-Hua LuChen LiSusan M HinikerSarah S Donaldson Melissa M Hudson Matthew J Krasin

Published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2021)

The integration of brentuximab vedotin in the frontline treatment of pediatric high-risk HL is highly tolerable, facilitated significant reduction in radiation exposure, and yielded excellent outcomes.

Keyphrases

hodgkin lymphoma
lymph node
type diabetes
radiation therapy
newly diagnosed
replacement therapy
weight loss